A prophylactic hepatitis B vaccine with a novel adjuvant system

Area of Science:

• Immunology
• Vaccinology
• Hepatitis B Research

Background:

• Recombinant hepatitis B vaccines achieve high seroprotection rates (91-100%).
• Certain populations (e.g., non-responders, haemodialysis patients, elderly) may not achieve adequate protection.
• Novel adjuvants represent a strategy to enhance vaccine immunogenicity.

Purpose of the Study:

• To evaluate the safety and immunogenicity of a new hepatitis B vaccine (HBsAg/SBAS4) utilizing the SBAS4 adjuvant system.
• To compare the immune response elicited by HBsAg/SBAS4 against established recombinant hepatitis B vaccines.
• To assess the vaccine's potential in populations with suboptimal responses to existing vaccines.

Main Methods:

• Pilot studies and several clinical assessments involving healthy populations, non-responders, and the elderly.
• Evaluation of in vivo humoral and in vitro cellular immune responses.
• Assessment of local reactogenicity and reported symptoms.

Main Results:

• The HBsAg/SBAS4 vaccine was generally well-tolerated.
• Compared to established vaccines, HBsAg/SBAS4 demonstrated increased local reactogenicity but few severe symptoms.
• The vaccine elicited a strong immune response, with faster protection and higher geometric mean titers (GMTs).

Conclusions:

• The HBsAg/SBAS4 vaccine, incorporating alum and 3-deacylated monophosphoryl lipid A (SBAS4), shows enhanced immunogenicity and potential for improved hepatitis B protection.
• This novel vaccine formulation may offer a viable option for individuals who do not respond adequately to current hepatitis B vaccines.
• SBAS4 adjuvant system shows promise in boosting immune responses for hepatitis B vaccination, particularly in vulnerable populations.